Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
BackgroundSintilimab plus chemotherapy (SIDCHM) is more effective than placebo plus chemotherapy (PLCHM) for advanced or metastatic esophageal squamous cell carcinoma (ESCC). However, considering the high cost of sintilimab, this study evaluated the cost-effectiveness of SIDCHM in comparison with PL...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.986762/full |
| _version_ | 1811205935071232000 |
|---|---|
| author | Maojin You Yufan Huang Zhongjie Cai Qingfeng Wu Wei Zhu Ying He Ruijia Chen |
| author_facet | Maojin You Yufan Huang Zhongjie Cai Qingfeng Wu Wei Zhu Ying He Ruijia Chen |
| author_sort | Maojin You |
| collection | DOAJ |
| description | BackgroundSintilimab plus chemotherapy (SIDCHM) is more effective than placebo plus chemotherapy (PLCHM) for advanced or metastatic esophageal squamous cell carcinoma (ESCC). However, considering the high cost of sintilimab, this study evaluated the cost-effectiveness of SIDCHM in comparison with PLCHM for advanced or metastatic ESCC from the Chinese healthcare system perspective.MethodsPolymorphic Markov models were constructed to simulate the course and cost of SIDCHM. Treatment drug costs were calculated at national list prices and clinical data, other costs, and utility values were extracted from the reference literature. Primary outcomes included quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). The robustness of the model was verified by one-way sensitivity analysis and probabilistic sensitivity analysis (PSA).ResultsSIDCHM obtained 1.03 QALYs at $24,044.49, whereas the effectiveness and cost of PLCHM were 0.67 QALYs and $14,166.24, respectively. The ICER for SIDCHM versus PLCHM was $23,458.08/QALY. The utility of the PFS state was the parameter that had the greatest effect on the ICER. The PSA showed that SIDCHM had an 86% probability of being cost-effective at the willingness-to-pay threshold of 3* Chinese gross domestic product per capita ($37,653/QALY).ConclusionFrom the Chinese healthcare system perspective, SIDCHM is considered a cost-effective treatment option compared with PLCHM as first-line therapy for advanced or metastatic ESCC. |
| first_indexed | 2024-04-12T03:38:34Z |
| format | Article |
| id | doaj.art-20d6cbf07fd84c08a388759fab1c9101 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T03:38:34Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-20d6cbf07fd84c08a388759fab1c91012022-12-22T03:49:20ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.986762986762Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinomaMaojin You0Yufan Huang1Zhongjie Cai2Qingfeng Wu3Wei Zhu4Ying He5Ruijia Chen6Department of Pharmacy, Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, ChinaDepartment of Pharmacy, Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, ChinaDepartment of Pharmacy, Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, ChinaDepartment of Pharmacy, Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, ChinaDepartment of Pharmacy, Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, ChinaDepartment of Emergency Medicine, Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, ChinaDepartment of Pharmacy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, ChinaBackgroundSintilimab plus chemotherapy (SIDCHM) is more effective than placebo plus chemotherapy (PLCHM) for advanced or metastatic esophageal squamous cell carcinoma (ESCC). However, considering the high cost of sintilimab, this study evaluated the cost-effectiveness of SIDCHM in comparison with PLCHM for advanced or metastatic ESCC from the Chinese healthcare system perspective.MethodsPolymorphic Markov models were constructed to simulate the course and cost of SIDCHM. Treatment drug costs were calculated at national list prices and clinical data, other costs, and utility values were extracted from the reference literature. Primary outcomes included quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). The robustness of the model was verified by one-way sensitivity analysis and probabilistic sensitivity analysis (PSA).ResultsSIDCHM obtained 1.03 QALYs at $24,044.49, whereas the effectiveness and cost of PLCHM were 0.67 QALYs and $14,166.24, respectively. The ICER for SIDCHM versus PLCHM was $23,458.08/QALY. The utility of the PFS state was the parameter that had the greatest effect on the ICER. The PSA showed that SIDCHM had an 86% probability of being cost-effective at the willingness-to-pay threshold of 3* Chinese gross domestic product per capita ($37,653/QALY).ConclusionFrom the Chinese healthcare system perspective, SIDCHM is considered a cost-effective treatment option compared with PLCHM as first-line therapy for advanced or metastatic ESCC.https://www.frontiersin.org/articles/10.3389/fonc.2022.986762/fullcost-effectivenesssintilimab plus chemotherapyesophageal squamous cell carcinomafirst-line treatmentplacebo plus chemotherapy |
| spellingShingle | Maojin You Yufan Huang Zhongjie Cai Qingfeng Wu Wei Zhu Ying He Ruijia Chen Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma Frontiers in Oncology cost-effectiveness sintilimab plus chemotherapy esophageal squamous cell carcinoma first-line treatment placebo plus chemotherapy |
| title | Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma |
| title_full | Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma |
| title_fullStr | Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma |
| title_full_unstemmed | Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma |
| title_short | Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma |
| title_sort | cost effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma |
| topic | cost-effectiveness sintilimab plus chemotherapy esophageal squamous cell carcinoma first-line treatment placebo plus chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.986762/full |
| work_keys_str_mv | AT maojinyou costeffectivenessanalysisofsintilimabpluschemotherapyforadvancedormetastaticesophagealsquamouscellcarcinoma AT yufanhuang costeffectivenessanalysisofsintilimabpluschemotherapyforadvancedormetastaticesophagealsquamouscellcarcinoma AT zhongjiecai costeffectivenessanalysisofsintilimabpluschemotherapyforadvancedormetastaticesophagealsquamouscellcarcinoma AT qingfengwu costeffectivenessanalysisofsintilimabpluschemotherapyforadvancedormetastaticesophagealsquamouscellcarcinoma AT weizhu costeffectivenessanalysisofsintilimabpluschemotherapyforadvancedormetastaticesophagealsquamouscellcarcinoma AT yinghe costeffectivenessanalysisofsintilimabpluschemotherapyforadvancedormetastaticesophagealsquamouscellcarcinoma AT ruijiachen costeffectivenessanalysisofsintilimabpluschemotherapyforadvancedormetastaticesophagealsquamouscellcarcinoma |